{"nctId":"NCT00533897","briefTitle":"Phase IIIB Subcutaneous Missed Dose Study","startDateStruct":{"date":"2007-11"},"conditions":["Rheumatoid Arthritis"],"count":270,"armGroups":[{"label":"Abatacept","type":"EXPERIMENTAL","interventionNames":["Drug: Abatacept"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Abatacept","otherNames":["Orencia","BMS-188667"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of Rheumatoid Arthritis\n* Disease Activity Score (DAS)28-C-Reactive Protein (CRP) score ≥ 3.2 and ≤5.1\n* On background methotrexate at least 3 months (≥10mg weekly)\n* Must be able to self injection or allow a care giver to do it for them\n* Discontinue all Biologics and Disease-Modifying Anti-rheumatic Drugs (DMARDs) except for methotrexate\n\nExclusion Criteria:\n\n* Participants who had prior exposure to abatacept or CTLA-4 Ig\n* Received treatment with rituximab.\n* Participants who have received treatment with leflunomide within 1 year of screening\n* Participants who have received treatment with immunoadsorption columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Double-blind Withdrawal (DBW) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibody Responses by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 169","description":"Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using an enzyme-linked immunosorbent assay (ELISA). Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]}]},{"type":"SECONDARY","title":"RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Placebo Group","description":"Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Lead-in (LI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time","description":"Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"LI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by Electrochemiluminescence (ECL) Over Time","description":"ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time","description":"Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. Samples were obtained during treatment (TRT) visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Re-introduction (RI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Groups","description":"Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Post Visits","description":"Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.","classes":[]},{"type":"SECONDARY","title":"DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time","description":"ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL At Post Visits","description":"ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.","classes":[]},{"type":"SECONDARY","title":"RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time by DBW Treatment Group","description":"Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time by DBW Treatment Group","description":"ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Short Term (ST); Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ELISA Antibody Responses by DBW Treatment Groups","description":"Serum samples from Abatacept-treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. ST was defined as the LI Period, the DBW Period, and the RI Period (Days 1-253).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Short Term: Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ECL Antibody Responses by DBW Treatment Groups","description":"ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"11.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Short Term: Mean Change in Disease Activity Score (DAS) 28 (Using C-Reactive Protein [CRP]) From Baseline Over Time by DBW Treatment Groups","description":"The DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\\> 5.1), low disease activity (≤ 3.2) and remission (\\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"0.10"},{"groupId":"OG001","value":"-0.87","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.07","spread":"0.14"},{"groupId":"OG001","value":"-1.10","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.14"},{"groupId":"OG001","value":"-1.62","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.76","spread":"0.12"},{"groupId":"OG001","value":"-1.89","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.97","spread":"0.11"},{"groupId":"OG001","value":"-1.88","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.78","spread":"0.18"},{"groupId":"OG001","value":"-1.69","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.81","spread":"0.17"},{"groupId":"OG001","value":"-1.54","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.03","spread":"0.18"},{"groupId":"OG001","value":"-1.49","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.14","spread":"0.16"},{"groupId":"OG001","value":"-1.92","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.20","spread":"0.17"},{"groupId":"OG001","value":"-2.04","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":"0.14"},{"groupId":"OG001","value":"-2.32","spread":"0.12"}]}]}]},{"type":"SECONDARY","title":"Short Term: Percentage of Participants Achieving Clinically Meaningful Improvement (CMI) in DAS 28 (CRP), Low Disease Activity (LDAS), or Clinical Remission Over Time by DBW Treatment Groups","description":"DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\\> 5.1), low disease activity (≤ 3.2) and remission (\\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":null},{"groupId":"OG001","value":"62.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"37.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"57.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"54.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","spread":null},{"groupId":"OG001","value":"28.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null},{"groupId":"OG001","value":"89.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"79.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","spread":null},{"groupId":"OG001","value":"63.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Short Term; Mean Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline Over Time by DBW Treatment Groups","description":"The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.06"},{"groupId":"OG001","value":"-0.30","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"0.05"},{"groupId":"OG001","value":"-0.35","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":"0.09"},{"groupId":"OG001","value":"-0.51","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"0.10"},{"groupId":"OG001","value":"-0.59","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"0.09"},{"groupId":"OG001","value":"-0.63","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"0.08"},{"groupId":"OG001","value":"-0.61","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"0.10"},{"groupId":"OG001","value":"-0.52","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.11"},{"groupId":"OG001","value":"-0.50","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.76","spread":"0.09"},{"groupId":"OG001","value":"-0.66","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"0.10"},{"groupId":"OG001","value":"-0.70","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.86","spread":"0.09"},{"groupId":"OG001","value":"-0.72","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Short Term; Percentage of Participants With HAQ-DI Response Over Time by DBW Treatment Groups","description":"The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":null},{"groupId":"OG001","value":"42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":null},{"groupId":"OG001","value":"62.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"67.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"69.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"67.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"62.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"74.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":null},{"groupId":"OG001","value":"74.3","spread":null}]}]}]},{"type":"SECONDARY","title":"LI; Mean Change in DAS 28 (CRP) From Baseline Over Time","description":"DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\\> 5.1), low disease activity (≤ 3.2) and remission (\\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.35","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.53","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"LI; Percentage of Participants With Clinically Meaningful Improvement in DAS (CRP) Over Time","description":"DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\\> 5.1), low disease activity (≤ 3.2) and remission (\\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW Period; Mean Change in DAS 28 (CRP) From DBW Period Baseline (Day 85) Over Time","description":"DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\\> 5.1), low disease activity (≤ 3.2) and remission (\\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.18"},{"groupId":"OG001","value":"0.16","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.17"},{"groupId":"OG001","value":"0.35","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.19"},{"groupId":"OG001","value":"0.40","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"DBW Period; Percentage of Participants With Rheumatoid Arthritis (RA) Flare Over Time","description":"A participant had an RA flare if at least 2 of the following criteria were met:\n\n* Doubling of tender and swollen joint count from Day 78\n* Increase in DAS28-CRP score ≥ 1.2 from Day 78\n* Prematurely discontinued from Double-blind Withdrawal Period (Period 2) and continued to Re-introduction Period (Period 3)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"9.5","spread":null}]}]}]},{"type":"SECONDARY","title":"RI Period; Mean Change in DAS 28 (CRP) From RI Period Baseline (Day 169) Over Time","description":"DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\\> 5.1), low disease activity (≤ 3.2) and remission (\\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.17"},{"groupId":"OG001","value":"-0.56","spread":"0.17"},{"groupId":"OG002","value":"-0.50","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.20"},{"groupId":"OG001","value":"-0.59","spread":"0.18"},{"groupId":"OG002","value":"-0.66","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"0.16"},{"groupId":"OG001","value":"-0.93","spread":"0.20"},{"groupId":"OG002","value":"-0.89","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"LI; Number of Participants With Deaths, Serious Adverse Events (SAEs), SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"LI Period; Number of Participants With AEs of Special Interest","description":"AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"LI; Number of Participants With Hematology Values Meeting the Marked Abnormality (MA) Criteria","description":"Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): \\>3 g/dL decrease from BL; Hematocrit: \\<0.75 \\* BL; Erythrocytes: \\<0.75 \\* BL; Platelets (PLT): \\<0.67 \\* LLN/\\>1.5 \\* ULN, or if BL \\< LLN then use \\<0.5 \\* BL and \\<100,000 mm\\^3; Leukocytes: \\<0.75 \\* LLN/ \\>1.25 \\* ULN, or if BL\\<LLN then use \\<0.8 \\* BL or \\>ULN, or if BL\\>ULN then use \\>1.2 \\* BL or \\<LLN; neutrophils+bands: \\<1.0 \\* 10\\^3 cells/ microliter (uL); eosinophils: \\>0.750 \\* 10\\^3 cells/uL; basophils: \\> 400 mm\\^3; monocytes: \\>2000 mm\\^3; lymphocytes: \\<0.750 \\* 10\\^3 cells/uL/ \\>7.50 \\* 10\\^3 cells/uL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"LI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria","description":"Marked abnormality criteria: Alkaline phosphatase (ALP): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; aspartate aminotransferase (AST): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; alanine aminotransferase (ALT): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; G-Glutamyl transferase (GGT): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; Bilirubin: \\>2\\* ULN, or if BL\\>ULN then use \\>4\\* BL; blood urea nitrogen (BUN): \\>2\\* BL; creatinine: \\>1.5\\* BL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"LI; Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria","description":"Marked abnormality criteria: Sodium (Na): \\<0.95\\*LLN/ \\>1.05\\*ULN, or if BL\\<LLN then use \\<0.95\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.05\\* BL or \\<LLN; potassium (K): \\<0.9\\* LLN/\\>1.1\\*ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; (Cl): \\<0.9\\* LLN/\\>1.1\\* ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; calcium (Ca): \\<0.8\\* LLN/\\>1.2\\* ULN, or if BL\\<LLN then use \\<0.75\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.25\\* BL or \\<LLN; phosphorous (P): \\<0.75\\* LLN/ \\>1.25\\* ULN, or if BL\\<LLN then use 0.67\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.33\\* BL or \\<LLN","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"LI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria","description":"MA criteria: serum glucose (Glu): \\<65 mg/dL/\\>220 mg/dL;fasting serum Glu: \\<0.8\\* LLN/\\>1.5\\*upper limits of normal (ULN),or if BL\\< lower limits of normal (LLN) then use 0.8\\*BL or \\> upper limits of normal (ULN),or if BL\\>ULN then use \\>2.0\\*BL or \\<LLN;total protein: \\<0.9\\*LLN/\\>1.1\\*ULN,or if BL\\<LLN then use \\<0.9\\*BL or \\>ULN,or if BL\\>UNL then use \\>1.1\\*BL or \\<LLN; albumin: \\<0.9\\*LLN,or if BL\\<LLN then use \\<0.75 BL;uric acid: \\>1.5\\*ULN,or if BL\\>ULN then use \\>2\\*BL. Urinalysis: Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells (RBCs), White Blood Cells (WBCs):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"LI Period; Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)","description":"Blood pressure was taken in participants while seated and measured in millimeters of mercury (mmHg). Pressures were assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.0","spread":"18.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.3","spread":"14.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.0","spread":"14.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.4","spread":"14.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120.3","spread":"14.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.0","spread":"15.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":"10.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":"9.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":"9.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":"9.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":"10.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":"9.45"}]}]}]},{"type":"SECONDARY","title":"LI Period; Mean Heart Rate (HR)","description":"Heart rate was taken in participants while seated and measured in beats per minute (bpm). Heart rate was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","spread":"9.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":"7.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":"9.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":"8.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.1","spread":"7.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":"8.64"}]}]}]},{"type":"SECONDARY","title":"LI Period; Mean Temperature (T)","description":"Temperature was taken in participants while seated and measured in degrees celsius. Temperature was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.39","spread":"0.387"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.34","spread":"0.351"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.39","spread":"0.371"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.38","spread":"0.329"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.33","spread":"0.333"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.35","spread":"0.368"}]}]}]},{"type":"SECONDARY","title":"DBW; Number of Participants With Death, Serious SAEs, Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW; Number of Participants With AEs of Special Interest","description":"AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria","description":"Marked abnormality criteria are: Hemoglobin (HGB): \\>3 g/dL decrease from BL; Hematocrit: \\<0.75 \\* BL; Erythrocytes: \\<0.75 \\* BL; Platelets (PLT): \\<0.67 \\* LLN/\\>1.5 \\* ULN, or if BL \\< LLN then use \\<0.5 \\* BL and \\<100,000 mm\\^3; Leukocytes: \\<0.75 \\* LLN/ \\>1.25 \\* ULN, or if BL\\<LLN then use \\<0.8 \\* BL or \\>ULN, or if BL\\>ULN then use \\>1.2 \\* BL or \\<LLN; neutrophils+bands: \\<1.0 \\* 10\\^3 cells/uL; eosinophils: \\>0.750 \\* 10\\^3 cells/uL; basophils: \\> 400 mm\\^3; monocytes: \\>2000 mm\\^3; lymphocytes: \\<0.750 \\* 10\\^3 cells/uL/ \\>7.50 \\* 10\\^3 cells/uL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria","description":"Marked abnormality criteria: Alkaline phosphatase (ALP): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; aspartate aminotransferase (AST): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; alanine aminotransferase (ALT): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; G-Glutamyl transferase (GGT): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; Bilirubin: \\>2\\* ULN, or if BL\\>ULN then use \\>4\\* BL; blood urea nitrogen (BUN): \\>2\\* BL; creatinine: \\>1.5\\* BL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria","description":"Marked abnormality criteria: Sodium (Na): \\<0.95\\*LLN/ \\>1.05\\*ULN, or if BL\\<LLN then use \\<0.95\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.05\\* BL or \\<LLN; potassium (K): \\<0.9\\* LLN/\\>1.1\\*ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; (Cl): \\<0.9\\* LLN/\\>1.1\\* ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; calcium (Ca): \\<0.8\\* LLN/\\>1.2\\* ULN, or if BL\\<LLN then use \\<0.75\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.25\\* BL or \\<LLN; phosphorous (P): \\<0.75\\* LLN/ \\>1.25\\* ULN, or if BL\\<LLN then use 0.67\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.33\\* BL or \\<LLN","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria","description":"MA criteria: serum glucose (Glu): \\<65 mg/dL/\\>220 mg/dL;fasting serum Glu: \\<0.8\\* LLN/\\>1.5\\*ULN,or if BL\\<LLN then use 0.8\\*BL or \\>ULN,or if BL\\>ULN then use \\>2.0\\*BL or \\<LLN;total protein: \\<0.9\\*LLN/\\>1.1\\*ULN,or if BL\\<LLN then use \\<0.9\\*BL or \\>UNL,or if BL\\>UNL then use \\>1.1\\*BL or \\<LLN; albumin: \\<0.9\\*LLN,or if BL\\<LLN then use \\<0.75 BL;uric acid: \\>1.5\\*ULN,or if BL\\>ULN then use \\>2\\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \\[RBCs\\], White Blood Cells \\[WBCs\\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"DBW; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Double Blind Period","description":"Blood pressures were taken in participants while seated, just prior to study drug injection, and measured in millimeters of mercury (mmHg).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119.4","spread":"13.29"},{"groupId":"OG001","value":"120.4","spread":"15.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120.3","spread":"12.73"},{"groupId":"OG001","value":"121.2","spread":"14.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119.6","spread":"13.87"},{"groupId":"OG001","value":"119.4","spread":"14.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":"10.44"},{"groupId":"OG001","value":"74.4","spread":"9.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":"10.46"},{"groupId":"OG001","value":"76.0","spread":"10.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":"9.51"},{"groupId":"OG001","value":"74.7","spread":"8.94"}]}]}]},{"type":"SECONDARY","title":"DBW Period; Mean Heart Rate (HR) During Period 2","description":"Heart Rate was taken in participants while seated, just prior to study drug injection, and measured in beats per minute (bpm)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":"8.07"},{"groupId":"OG001","value":"73.9","spread":"8.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.9","spread":"9.35"},{"groupId":"OG001","value":"74.5","spread":"8.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":"8.19"},{"groupId":"OG001","value":"74.2","spread":"8.50"}]}]}]},{"type":"SECONDARY","title":"DBW Period; Mean Temperature (T) During Period II","description":"Participants were seated and temperature taken just prior to study drug injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.34","spread":"0.488"},{"groupId":"OG001","value":"36.44","spread":"0.370"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.31","spread":"0.355"},{"groupId":"OG001","value":"36.36","spread":"0.347"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.38","spread":"0.364"},{"groupId":"OG001","value":"36.32","spread":"0.373"}]}]}]},{"type":"SECONDARY","title":"RI; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"RI; Number of Participants With AEs of Special Interest","description":"AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"RI; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria","description":"Marked abnormality criteria are: Hemoglobin (HGB): \\>3 g/dL decrease from BL; Hematocrit: \\<0.75 \\* BL; Erythrocytes: \\<0.75 \\* BL; Platelets (PLT): \\<0.67 \\* LLN/\\>1.5 \\* ULN, or if BL \\< LLN then use \\<0.5 \\* BL and \\<100,000 mm\\^3; Leukocytes: \\<0.75 \\* LLN/ \\>1.25 \\* ULN, or if BL\\<LLN then use \\<0.8 \\* BL or \\>ULN, or if BL\\>ULN then use \\>1.2 \\* BL or \\<LLN; neutrophils+bands: \\<1.0 \\* 10\\^3 cells/uL; eosinophils: \\>0.750 \\* 10\\^3 cells/uL; basophils: \\> 400 mm\\^3; monocytes: \\>2000 mm\\^3; lymphocytes: \\<0.750 \\* 10\\^3 cells/uL/ \\>7.50 \\* 10\\^3 cells/uL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"RI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria","description":"Marked abnormality criteria: Alkaline phosphatase (ALP): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; aspartate aminotransferase (AST): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; alanine aminotransferase (ALT): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; G-Glutamyl transferase (GGT): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; Bilirubin: \\>2\\* ULN, or if BL\\>ULN then use \\>4\\* BL; blood urea nitrogen (BUN): \\>2\\* BL; creatinine: \\>1.5\\* BL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"RI; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria","description":"Marked abnormality criteria: Sodium (Na): \\<0.95\\*LLN/ \\>1.05\\*ULN, or if BL\\<LLN then use \\<0.95\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.05\\* BL or \\<LLN; potassium (K): \\<0.9\\* LLN/\\>1.1\\*ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; (Cl): \\<0.9\\* LLN/\\>1.1\\* ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; calcium (Ca): \\<0.8\\* LLN/\\>1.2\\* ULN, or if BL\\<LLN then use \\<0.75\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.25\\* BL or \\<LLN; phosphorous (P): \\<0.75\\* LLN/ \\>1.25\\* ULN, or if BL\\<LLN then use 0.67\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.33\\* BL or \\<LLN","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"RI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria","description":"MA criteria: serum glucose (Glu): \\<65 mg/dL/\\>220 mg/dL;fasting serum Glu: \\<0.8\\* LLN/\\>1.5\\*ULN,or if BL\\<LLN then use 0.8\\*BL or \\>ULN,or if BL\\>ULN then use \\>2.0\\*BL or \\<LLN;total protein: \\<0.9\\*LLN/\\>1.1\\*ULN,or if BL\\<LLN then use \\<0.9\\*BL or \\>UNL,or if BL\\>UNL then use \\>1.1\\*BL or \\<LLN; albumin: \\<0.9\\*LLN,or if BL\\<LLN then use \\<0.75 BL;uric acid: \\>1.5\\*ULN,or if BL\\>ULN then use \\>2\\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \\[RBCs\\], White Blood Cells \\[WBCs\\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"RI Period; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Period III","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.3","spread":"15.81"},{"groupId":"OG001","value":"116.6","spread":"14.78"},{"groupId":"OG002","value":"118.9","spread":"13.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119.1","spread":"14.07"},{"groupId":"OG001","value":"118.4","spread":"15.62"},{"groupId":"OG002","value":"121.0","spread":"14.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117.8","spread":"14.19"},{"groupId":"OG001","value":"118.8","spread":"16.55"},{"groupId":"OG002","value":"121.0","spread":"16.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118.3","spread":"15.00"},{"groupId":"OG001","value":"116.1","spread":"14.86"},{"groupId":"OG002","value":"120.3","spread":"16.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":"10.46"},{"groupId":"OG001","value":"73.5","spread":"9.61"},{"groupId":"OG002","value":"74.9","spread":"9.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":"9.24"},{"groupId":"OG001","value":"71.6","spread":"7.66"},{"groupId":"OG002","value":"74.9","spread":"9.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.6","spread":"10.56"},{"groupId":"OG001","value":"73.7","spread":"7.84"},{"groupId":"OG002","value":"75.5","spread":"10.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":"11.24"},{"groupId":"OG001","value":"71.5","spread":"9.92"},{"groupId":"OG002","value":"76.3","spread":"11.02"}]}]}]},{"type":"SECONDARY","title":"RI Period; Mean Heart Rate (HR) During Period III","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.4","spread":"8.54"},{"groupId":"OG001","value":"73.8","spread":"10.13"},{"groupId":"OG002","value":"74.1","spread":"9.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":"7.52"},{"groupId":"OG001","value":"75.1","spread":"7.25"},{"groupId":"OG002","value":"70.9","spread":"8.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":"7.0"},{"groupId":"OG001","value":"73.9","spread":"7.43"},{"groupId":"OG002","value":"73.2","spread":"7.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.6","spread":"8.53"},{"groupId":"OG001","value":"74.4","spread":"7.87"},{"groupId":"OG002","value":"74.3","spread":"9.36"}]}]}]},{"type":"SECONDARY","title":"RI Period; Mean Temperature (T) During Period III","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.32","spread":"0.423"},{"groupId":"OG001","value":"36.29","spread":"0.473"},{"groupId":"OG002","value":"36.26","spread":"0.396"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.39","spread":"0.405"},{"groupId":"OG001","value":"36.37","spread":"0.424"},{"groupId":"OG002","value":"36.35","spread":"0.354"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.27","spread":"0.375"},{"groupId":"OG001","value":"36.38","spread":"0.444"},{"groupId":"OG002","value":"36.36","spread":"0.320"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.28","spread":"0.473"},{"groupId":"OG001","value":"36.32","spread":"0.587"},{"groupId":"OG002","value":"36.33","spread":"0.383"}]}]}]},{"type":"SECONDARY","title":"Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ELISA by RI Treatment Groups","description":"Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ELISA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.17","spread":"10.510"},{"groupId":"OG001","value":"33.73","spread":"NA"},{"groupId":"OG002","value":"18.05","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.45","spread":"10.578"},{"groupId":"OG001","value":"35.67","spread":"10.365"},{"groupId":"OG002","value":"22.76","spread":"8.740"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"34.18","spread":"NA"},{"groupId":"OG002","value":"21.69","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.86","spread":"9.514"},{"groupId":"OG001","value":"31.70","spread":"10.635"},{"groupId":"OG002","value":"29.24","spread":"13.897"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.49","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"26.23","spread":"0.776"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.17","spread":"9.856"},{"groupId":"OG001","value":"28.26","spread":"10.211"},{"groupId":"OG002","value":"26.80","spread":"10.547"}]}]}]},{"type":"SECONDARY","title":"Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ECL by RI Treatment Groups","description":"Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ECL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.72","spread":"10.479"},{"groupId":"OG001","value":"35.61","spread":"10.207"},{"groupId":"OG002","value":"22.65","spread":"8.662"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.86","spread":"9.514"},{"groupId":"OG001","value":"31.79","spread":"10.460"},{"groupId":"OG002","value":"29.06","spread":"13.776"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.75","spread":"9.872"},{"groupId":"OG001","value":"28.26","spread":"10.211"},{"groupId":"OG002","value":"26.28","spread":"10.645"}]}]}]},{"type":"SECONDARY","title":"ST; Number of Participants Positive for Anti-nuclear Antibody (ANA), Anti-double Stranded DNA Antibody (dsDNA), or Rheumatoid Factor (RF) at Day 253 According to Baseline Status (Negative at Baseline or Positive at Baseline) by DBW Treatment Groups","description":"Venous blood was collected and tested for anti-nuclear antibodies, anti-dsDNA antibodies, and rheumatoid factor. ANA were detected by means of immunofluorescent antibodies. An anti-DNA radioimmunoassay was used for detection of anti-dsDNA antibodies (Diagnostic Products Corporation). RF was measured by an immunoturbidimetric assay (Roche Tina-Quant). Determinations of antibody or RF status were made at baseline and Day 253.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: DAS28-CRP Mean Change From Baseline (Day 1) Over Time - All Participants Treated in LTE","description":"DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. DAS28-CRP has numeric thresholds defining high disease activity (\\> 5.1), low disease activity (≤ 3.2) and remission (\\< 2.6). Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"0.14"},{"groupId":"OG001","value":"-0.79","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"0.21"},{"groupId":"OG001","value":"-1.91","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"-2.29","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.51","spread":"0.16"},{"groupId":"OG001","value":"-2.34","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.83","spread":"0.19"},{"groupId":"OG001","value":"-2.23","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.86","spread":"0.19"},{"groupId":"OG001","value":"-2.28","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.81","spread":"0.19"},{"groupId":"OG001","value":"-2.16","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.94","spread":"0.18"},{"groupId":"OG001","value":"-2.12","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.70","spread":"0.15"},{"groupId":"OG001","value":"-2.20","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.86","spread":"0.20"},{"groupId":"OG001","value":"-2.55","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"LTE: Percent of Participants Who Achieved Clinical Remission in the Long Term Extension - All Participants Treated in LTE","description":"DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. Clinical remission=DAS28-CRP score\\<2.6. Percent=Number of participants meeting remission divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available (NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"36.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"59.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"59.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null},{"groupId":"OG001","value":"54.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null},{"groupId":"OG001","value":"51.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null},{"groupId":"OG001","value":"59.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"59.7","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Percent of Participants With Low Disease Activity in Long Term Extension: All Participants Treated in LTE","description":"DAS28:continuous disease measure composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. Low disease activity score: ≤ 3.2. Percent=Number of participants with Low Disease Activity divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"66.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"75.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6","spread":null},{"groupId":"OG001","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"73.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null},{"groupId":"OG001","value":"67.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.0","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"88.1","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Percent of Participants With HAQ Response Over Time - All Participants Treated in LTE","description":"The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index (DI) was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ DI. Percent=number of participants with HAQ response divided by number of participants in the analysis. Since Period I Non-responders proceeded directly to the LTE at the end of Period I (Day 85), study days do not represent treatment days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"44.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"68.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.5","spread":null},{"groupId":"OG001","value":"74.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"78.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null},{"groupId":"OG001","value":"73.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"72.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null},{"groupId":"OG001","value":"70.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"70.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null},{"groupId":"OG001","value":"71.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"76.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8","spread":null},{"groupId":"OG001","value":"73.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"73.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"68.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"70.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"70.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"72.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.9","spread":null},{"groupId":"OG001","value":"69.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"74.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"74.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0","spread":null},{"groupId":"OG001","value":"73.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Overall Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses (ECL Method) for On-Treatment Visits, Post Last Dose Visits, and Overall Study - All Participants Treated in LTE","description":"Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using electrochemiluminescence (ECL). The percent of participants with a positive abatacept induced immunogenicity response against cytotoxic T-lymphocyte antigen 4 (CTLA4) and possibly immunoglobulin (Ig), or against Ig and/or Junction Region was calculated by number of participants with a positive response divided by number of participants evaluated. Overall for on-treatment includes treatment visits on Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, and 1989.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Number of Participants With Death, Related SAEs, SAEs Leading to Discontinuation, Related AEs, or AEs Leading to Discontinuation During Long Term Extension (LTE)","description":"AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. SAEs include hospitalizations for elective surgical procedures.All deaths reported during the LTE including those that occurred \\> 56 days after the last dose. Related AE or SAE defined as AE or SAE with Certain, Probable, Possible, or Missing relationship to study medication. All participants who completed the ST period could enter the open label LTE on Day 253; LI Period 1 non-responders could directly enter the LTE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Number of Participants With AEs of Special Interest During LTE","description":"AEs of special interest in LTE are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies, local injection site reaction (pre-specified AEs occurring at the site of SC injection) and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria During LTE","description":"Marked abnormality criteria are: Hemoglobin (HGB): \\>3 g/dL decrease from BL; Hematocrit: \\<0.75 \\* BL; Erythrocytes: \\<0.75 \\* BL; Platelets (PLT): \\<0.67 \\* LLN/\\>1.5 \\* ULN, or if BL \\< LLN then use \\<0.5 \\* BL and \\<100,000 mm\\^3; Leukocytes: \\<0.75 \\* LLN/ \\>1.25 \\* ULN, or if BL\\<LLN then use \\<0.8 \\* BL or \\>ULN, or if BL\\>ULN then use \\>1.2 \\* BL or \\<LLN; neutrophils+bands: \\<1.0 \\* 10\\^3 cells/uL; eosinophils: \\>0.750 \\* 10\\^3 cells/uL; basophils: \\> 400 mm\\^3; monocytes: \\>2000 mm\\^3; lymphocytes: \\<0.750 \\* 10\\^3 cells/uL/ \\>7.50 \\* 10\\^3 cells/uL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria During LTE","description":"Marked abnormality criteria: Alkaline phosphatase (ALP): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; aspartate aminotransferase (AST): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; alanine aminotransferase (ALT): \\>3\\* ULN, or if BL\\>ULN then use \\>4\\* BL; G-Glutamyl transferase (GGT): \\>2\\* ULN, or if BL\\>ULN then use \\>3\\* BL; Bilirubin: \\>2\\* ULN, or if BL\\>ULN then use \\>4\\* BL; blood urea nitrogen (BUN): \\>2\\* BL; creatinine: \\>1.5\\* BL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria During LTE","description":"Marked abnormality criteria: Sodium (Na): \\<0.95\\*LLN/ \\>1.05\\*ULN, or if BL\\<LLN then use \\<0.95\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.05\\* BL or \\<LLN; potassium (K): \\<0.9\\* LLN/\\>1.1\\*ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; (Cl): \\<0.9\\* LLN/\\>1.1\\* ULN, or if BL\\<LLN then use \\<0.9\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.1\\* BL or \\<LLN; calcium (Ca): \\<0.8\\* LLN/\\>1.2\\* ULN, or if BL\\<LLN then use \\<0.75\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.25\\* BL or \\<LLN; phosphorous (P): \\<0.75\\* LLN/ \\>1.25\\* ULN, or if BL\\<LLN then use 0.67\\* BL or \\>ULN, or if BL\\>ULN then use\\>1.33\\* BL or \\<LLN","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria During LTE","description":"MA criteria: serum glucose (Glu): \\<65 mg/dL/\\>220 mg/dL;fasting serum Glu: \\<0.8\\* LLN/\\>1.5\\*ULN,or if BL\\<LLN then use 0.8\\*BL or \\>ULN,or if BL\\>ULN then use \\>2.0\\*BL or \\<LLN;total protein: \\<0.9\\*LLN/\\>1.1\\*ULN,or if BL\\<LLN then use \\<0.9\\*BL or \\>UNL,or if BL\\>UNL then use \\>1.1\\*BL or \\<LLN; albumin: \\<0.9\\*LLN,or if BL\\<LLN then use \\<0.75 BL;uric acid: \\>1.5\\*ULN,or if BL\\>ULN then use \\>2\\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \\[RBCs\\], White Blood Cells \\[WBCs\\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"LTE: Mean Seated Systolic Blood Pressure (SBP) During LTE","description":"During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.7","spread":"13.76"},{"groupId":"OG001","value":"120.8","spread":"15.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.7","spread":"14.26"},{"groupId":"OG001","value":"120.4","spread":"15.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.9","spread":"15.08"},{"groupId":"OG001","value":"119.5","spread":"14.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.0","spread":"14.48"},{"groupId":"OG001","value":"120.7","spread":"15.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.7","spread":"13.26"},{"groupId":"OG001","value":"118.7","spread":"15.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.2","spread":"11.77"},{"groupId":"OG001","value":"121.5","spread":"17.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126.6","spread":"12.66"},{"groupId":"OG001","value":"120.6","spread":"15.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.9","spread":"11.92"},{"groupId":"OG001","value":"122.5","spread":"14.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.3","spread":"12.23"},{"groupId":"OG001","value":"122.9","spread":"15.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.2","spread":"18.41"},{"groupId":"OG001","value":"123.7","spread":"15.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125.8","spread":"11.17"},{"groupId":"OG001","value":"123.0","spread":"15.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124.9","spread":"11.04"},{"groupId":"OG001","value":"119.7","spread":"13.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124.5","spread":"13.11"},{"groupId":"OG001","value":"121.9","spread":"14.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124.1","spread":"14.75"},{"groupId":"OG001","value":"125.5","spread":"18.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126.1","spread":"15.06"},{"groupId":"OG001","value":"122.3","spread":"14.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.4","spread":"9.09"},{"groupId":"OG001","value":"120.3","spread":"13.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.0","spread":"13.08"},{"groupId":"OG001","value":"121.9","spread":"14.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125.4","spread":"13.22"},{"groupId":"OG001","value":"124.3","spread":"10.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.8","spread":"13.14"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124.6","spread":"9.56"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113.0","spread":"0"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"LTE: Mean Seated Diastolic Blood Pressure (DBP) During LTE","description":"During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":"6.69"},{"groupId":"OG001","value":"75.4","spread":"11.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.1","spread":"10.42"},{"groupId":"OG001","value":"75.1","spread":"8.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":"9.48"},{"groupId":"OG001","value":"73.8","spread":"9.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":"8.43"},{"groupId":"OG001","value":"75.4","spread":"9.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":"8.81"},{"groupId":"OG001","value":"74.8","spread":"9.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":"8.42"},{"groupId":"OG001","value":"76.1","spread":"9.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":"9.39"},{"groupId":"OG001","value":"76.4","spread":"9.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.8","spread":"8.41"},{"groupId":"OG001","value":"75.5","spread":"9.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":"6.55"},{"groupId":"OG001","value":"76.1","spread":"9.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":"7.11"},{"groupId":"OG001","value":"75.9","spread":"9.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":"6.32"},{"groupId":"OG001","value":"75.9","spread":"8.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":"8.18"},{"groupId":"OG001","value":"75.6","spread":"8.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.3","spread":"6.08"},{"groupId":"OG001","value":"75.6","spread":"9.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":"9.18"},{"groupId":"OG001","value":"77.1","spread":"10.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":"8.14"},{"groupId":"OG001","value":"76.0","spread":"9.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":"5.89"},{"groupId":"OG001","value":"74.9","spread":"9.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":"9.47"},{"groupId":"OG001","value":"75.4","spread":"9.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":"7.99"},{"groupId":"OG001","value":"78.3","spread":"7.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":"7.96"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":"5.31"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":"0"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"LTE: Mean Heart Rate (HR) During LTE","description":"During LTE, heart rate was taken in participants while seated, measured in beats per minute (bpm) and was assessed at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.3","spread":"7.07"},{"groupId":"OG001","value":"74.9","spread":"8.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":"7.76"},{"groupId":"OG001","value":"75.7","spread":"8.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":"6.62"},{"groupId":"OG001","value":"75.7","spread":"7.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":"6.62"},{"groupId":"OG001","value":"74.7","spread":"8.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":"6.96"},{"groupId":"OG001","value":"76.0","spread":"8.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":"8.60"},{"groupId":"OG001","value":"75.1","spread":"8.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":"7.57"},{"groupId":"OG001","value":"76.2","spread":"9.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":"7.71"},{"groupId":"OG001","value":"76.3","spread":"8.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":"8.00"},{"groupId":"OG001","value":"76.5","spread":"10.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":"8.35"},{"groupId":"OG001","value":"75.0","spread":"9.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":"6.89"},{"groupId":"OG001","value":"75.3","spread":"9.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":"7.97"},{"groupId":"OG001","value":"74.4","spread":"8.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":"8.54"},{"groupId":"OG001","value":"73.6","spread":"8.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":"7.67"},{"groupId":"OG001","value":"76.8","spread":"7.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":"7.34"},{"groupId":"OG001","value":"75.1","spread":"8.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":"7.77"},{"groupId":"OG001","value":"75.2","spread":"8.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":"6.86"},{"groupId":"OG001","value":"74.7","spread":"8.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":"7.80"},{"groupId":"OG001","value":"78.2","spread":"6.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":"8.97"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":"9.53"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":"0"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"LTE: Mean Temperature (T) During LTE","description":"During LTE, temperature was taken in participants while seated, measured in degrees celsius and was assessed at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.29","spread":"0.285"},{"groupId":"OG001","value":"36.31","spread":"0.370"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.35","spread":"0.370"},{"groupId":"OG001","value":"36.30","spread":"0.393"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.40","spread":"0.354"},{"groupId":"OG001","value":"36.30","spread":"0.294"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.42","spread":"0.358"},{"groupId":"OG001","value":"36.30","spread":"0.312"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.38","spread":"0.248"},{"groupId":"OG001","value":"36.37","spread":"0.316"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.47","spread":"0.252"},{"groupId":"OG001","value":"36.27","spread":"0.332"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.49","spread":"0.284"},{"groupId":"OG001","value":"36.30","spread":"0.324"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.44","spread":"0.254"},{"groupId":"OG001","value":"36.26","spread":"0.325"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.48","spread":"0.259"},{"groupId":"OG001","value":"36.30","spread":"0.295"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.35","spread":"0.370"},{"groupId":"OG001","value":"36.28","spread":"0.278"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.41","spread":"0.277"},{"groupId":"OG001","value":"36.24","spread":"0.327"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.39","spread":"0.256"},{"groupId":"OG001","value":"36.24","spread":"0.276"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.29","spread":"0.285"},{"groupId":"OG001","value":"36.23","spread":"0.232"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.32","spread":"0.253"},{"groupId":"OG001","value":"36.23","spread":"0.242"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.34","spread":"0.223"},{"groupId":"OG001","value":"36.24","spread":"0.198"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.37","spread":"0.215"},{"groupId":"OG001","value":"36.20","spread":"0.214"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.35","spread":"0.178"},{"groupId":"OG001","value":"36.24","spread":"0.249"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.25","spread":"0.315"},{"groupId":"OG001","value":"36.26","spread":"0.228"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.37","spread":"0.211"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.35","spread":"0.139"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.40","spread":"0"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":10},"commonTop":["Upper respiratory tract infection","Bronchitis","Urinary tract infection","Sinusitis","Influenza"]}}}